CMPX vs MA · $367.4M cap vs P/E 38, rev $32.79B
Compass Therapeutics Inc. (CMPX) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
CMPX does not have a complete income-statement cache yet.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
CMPX currently screens at market cap $367.4M. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the CMPX and MA stock pages for the full models.
Not investment advice.